NOW AVAILABLE: For the European Hepatitis C Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

AbbVie maintained its lead in terms of the proportion of the promotional volume received, with Exviera/Viekirax materials distributed in all countries analyzed. Epclusa’s July approval was announced in Germany alongside an expected availability date of July 18, 2016, while in the UK, Janssen stated that it would not renew Incivo’s license when marketing authorizations ceased in September 2016. Clinical trial data continued to be a focus across brands, while an increase was observed in DTC materials, most of which were unbranded patient newsletters. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-Q3-2016-Hep-C

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com